{
    "name": "prabotulinumtoxinA",
    "comment": "Rx",
    "other_names": [
        "Jeuveau",
        "prabotulinumtoxinA-xvfs"
    ],
    "classes": [
        "Neuromuscular Blockers",
        "Botulinum Toxins"
    ],
    "source": "https://reference.medscape.com/drug/jeuveau-prabotulinumtoxinA-1000292",
    "pregnancy": {
        "common": [
            "Limited available data on use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes",
            "An embryofetal developmental study conducted in pregnant rats revealed no treatment-related effects to the developing fetus when administered intramuscularly during organogenesis at doses up to 12 times the maximum recommended human dose (MRHD)"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information regarding the presence of prabotulinumtoxinA in human or animal milk, its effects on the breastfed infant, or on milk production",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Effects of all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects",
                "Symptoms have been reported hours to weeks after injection and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties",
                "Swallowing and breathing difficulties can be life threatening, and deaths have been reported",
                "PrabotulinumtoxinA is not approved for treatment of spasticity or any conditions other than glabellar lines"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation",
                "Presence of infection at the proposed injection site(s)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Postmarketing safety data from other approved botulinum toxins suggest that botulinum toxin effects may be observed beyond the local injection site; not approved for spasticity or any conditions other than glabellar lines",
                "Not interchangeable with other preparations of botulinum toxin products and cannot be compared with nor converted into units of any other botulinum toxin products assessed with any other specific assay method",
                "Serious adverse reactions (eg, excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes) reported in patients who received botulinum toxin injections for unapproved uses",
                "Serious and/or immediate hypersensitivity reactions reported",
                "Cardiovascular adverse events (eg, arrhythmia, myocardial infarction), some with fatal outcomes, reported following botulinum toxin administration",
                "Patients with neuromuscular disorders may be at increased risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from treatment",
                "Treatment can result in swallowing or breathing difficulties",
                "Seek immediate medical attention if respiratory, speech or swallowing difficulties occur",
                "Use with caution in patients with compromised respiratory function or dysphagia",
                "Deaths, as a complication of severe dysphagia, have been reported after treatment with botulinum toxin",
                "Caution if inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s)",
                "Caution in patients who have marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin or subjects who may not respond to 20 units of botulinum toxin, (eg, inability to substantially lessen glabellar lines even by physically spreading them apart)",
                "Dry eye reported; reduced tear production, reduced blinking, and corneal disorders may occur",
                "Product contains albumin; based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for viral transmission of variant Creutzfeldt-Jakob disease (vCJD)",
                "Caution if coadministered with aminoglycosides or other agents interfering with neuromuscular transmission (eg, anticholinergic drugs, other botulinum neurotoxin products, muscle relaxants); may potentiate prabotulinumtoxinA effect"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abobotulinumtoxinA",
            "description": {
                "common": "abobotulinumtoxinA, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Effect of administering different botulinum toxins simultaneously or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to resolution of the effects of a previously administered botulinum toxin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "incobotulinumtoxinA",
            "description": {
                "common": "prabotulinumtoxinA, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Effect of administering different botulinum toxins simultaneously or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to resolution of the effects of a previously administered botulinum toxin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "onabotulinumtoxinA, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Effect of administering different botulinum toxins simultaneously or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to resolution of the effects of a previously administered botulinum toxin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amikacin liposome inhalation",
            "description": {
                "common": "amikacin liposome inhalation increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arbaclofen",
            "description": {
                "common": "arbaclofen increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atropine",
            "description": {
                "common": "atropine, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "baclofen",
            "description": {
                "common": "baclofen increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carisoprodol",
            "description": {
                "common": "carisoprodol increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorzoxazone",
            "description": {
                "common": "chlorzoxazone increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "cyclobenzaprine increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dantrolene",
            "description": {
                "common": "dantrolene increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darifenacin",
            "description": {
                "common": "darifenacin, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "diazepam increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dicyclomine",
            "description": {
                "common": "dicyclomine, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "fesoterodine, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gentamicin",
            "description": {
                "common": "gentamicin increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glycopyrrolate",
            "description": {
                "common": "glycopyrrolate, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyoscyamine",
            "description": {
                "common": "hyoscyamine, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyoscyamine spray",
            "description": {
                "common": "hyoscyamine spray, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaxalone",
            "description": {
                "common": "metaxalone increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methocarbamol",
            "description": {
                "common": "methocarbamol increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methscopolamine",
            "description": {
                "common": "methscopolamine, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "neomycin PO increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "orphenadrine increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "plazomicin",
            "description": {
                "common": "plazomicin increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propantheline",
            "description": {
                "common": "propantheline, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases effects of prabotulinumtoxinA by Other (see comment). Use Caution/Monitor. \nComment: Magnesium may potentiate the effects of the neuromuscular blocking agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases effects of prabotulinumtoxinA by Other (see comment). Use Caution/Monitor. \nComment: Magnesium may potentiate the effects of the neuromuscular blocking agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solifenacin",
            "description": {
                "common": "solifenacin, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptomycin",
            "description": {
                "common": "streptomycin increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin",
            "description": {
                "common": "tobramycin increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolterodine",
            "description": {
                "common": "tolterodine, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trospium chloride",
            "description": {
                "common": "trospium chloride, prabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "12"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "3"
        },
        {
            "name": "Eyelid ptosis",
            "percent": "2"
        },
        {
            "name": "Increased white blood cell count",
            "percent": "1"
        },
        {
            "name": "Injection site",
            "percent": null
        },
        {
            "name": "Localized pain",
            "percent": null
        },
        {
            "name": "infection",
            "percent": null
        },
        {
            "name": "inflammation",
            "percent": null
        },
        {
            "name": "tenderness",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "and",
            "percent": null
        },
        {
            "name": "or bleeding",
            "percent": null
        },
        {
            "name": "bruising",
            "percent": null
        },
        {
            "name": "Needle",
            "percent": null
        },
        {
            "name": "related pain and",
            "percent": null
        },
        {
            "name": "or anxiety",
            "percent": null
        }
    ]
}